Novartis 4Q Revenues: $14.8 billion (+4%) 4Q Earnings: $1.2 billion (-47%) FY Revenues: $58.6 billion (+16%) FY Earnings: $9.2 billion (-7%) Comments: Pharmaceuticals sales in quarter were up 4% to $8.3 billion. Alcon sales were $2.4 billion (+6%). Sandoz sales declined 5% to $2.3 billion due to additional competition for enoxaparin, the generic version of Lovenox. Vaccines and Diagnostics sales grew 86% to $671 million. Consumer Health was down 7% to $1.1 billion related to the temporary s...